Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling.

There is increasing evidence for a role of 5-hydroxytrypta-mine-6 (5-HT6) receptors in cognitive function. In the rat and human brain, 5-HT6 receptors are widely expressed and highly enriched in the basal ganglia. However, in the mouse brain, only very low levels of 5-HT6 receptor mRNA and receptor protein, measured by TaqMan reverse transcriptase-polymerase chain reaction and selective radioligand binding, could be detected, with no evidence of enrichment in the basal ganglia. The mouse receptor was cloned and transiently expressed in human embryonic kidney 293 cells to characterize its pharmacological profile. Despite significant sequence homology between human, rat, and mouse 5-HT6 receptors, the pharmacological profile of the mouse receptor was significantly different from the rat and human receptors. Four amino acid residues, conserved in rat and human and divergent in mouse receptors, were identified, and various mutant receptors were generated and their pharmacologies studied. Residues 188 (tyrosine in mouse, phenylalanine in rat and human) in transmembrane region 5 and 290 (serine in mouse, asparagine in rat and human) in transmembrane region 6 were identified as key amino acids responsible for the different pharmacological profiles. Molecular modeling of the receptor and docking of selective and nonselective compounds was undertaken to elucidate the ligand receptor interactions. The binding pocket was predicted to be different in the mouse compared with rat and human 5-HT6 receptors, and the models were in excellent agreement with the observed mutation results and have been used extensively in the design of further selective 5-HT6 antagonists.

[1]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[2]  J. Hagan,et al.  5-HT6 receptor antagonists enhance retention of a water maze task in the rat , 2001, Psychopharmacology.

[3]  M. Yoshioka,et al.  Central distribution and function of 5-HT6 receptor subtype in the rat brain. , 1998, Life sciences.

[4]  Paul J. Harrison,et al.  5‐HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: Autoradiographic studies with [125I]SB‐258585 , 2002, Synapse.

[5]  L. Lanfumey,et al.  Antibodies and Antisense Oligonucleotide for Probing the Distribution and Putative Functions of Central 5-HT6Receptors , 1999, Neuropsychopharmacology.

[6]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[7]  A. Sleight,et al.  Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats , 1999, British journal of pharmacology.

[8]  D. Middlemiss,et al.  Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist , 2000, British journal of pharmacology.

[9]  D. Sibley,et al.  Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.

[10]  Paul J. Harrison,et al.  The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585 , 2002, Brain Research.

[11]  W. P. Bowen,et al.  Nonlinear regression using spreadsheets. , 1995, Trends in pharmacological sciences.

[12]  A. Sleight,et al.  A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.

[13]  A. Sleight,et al.  Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors , 1998, British journal of pharmacology.

[14]  Manuel C. Peitsch.  Membrane protein models , 1997 .

[15]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[16]  J. C. Roberts,et al.  Molecular and pharmacological characterization of a functional tachykinin NK3 receptor cloned from the rabbit iris sphincter muscle , 1999, British journal of pharmacology.

[17]  A. Meneses.  Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation , 2001, Behavioural Brain Research.

[18]  F. Monsma,et al.  Identification of Residues in Transmembrane Regions III and VI that Contribute to the Ligand Binding Site of the Serotonin 5‐HT6 Receptor , 1998, Journal of neurochemistry.

[19]  C. Humblet,et al.  G‐Protein Coupled Receptors: Models, Mutagenesis, and Drug Design , 1998 .

[20]  L. Lanfumey,et al.  Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system , 1997, Brain Research.

[21]  R. Kohen,et al.  Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. , 2001, Brain research. Molecular brain research.

[22]  B. Roth,et al.  Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. , 2000, Molecular pharmacology.

[23]  D. Middlemiss,et al.  Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. , 2000, British journal of pharmacology.

[24]  F E Blaney,et al.  Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. , 2001, Journal of medicinal chemistry.

[25]  B. Roth,et al.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.

[26]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[27]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[28]  B. Roth,et al.  A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[29]  A. Brown,et al.  5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. , 1999, Journal of medicinal chemistry.

[30]  J. Schwartz,et al.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. , 1993, Biochemical and biophysical research communications.

[31]  Paul J. Harrison,et al.  The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. , 2002, Brain research.

[32]  D. Middlemiss,et al.  Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue , 2000 .

[33]  D. Sibley,et al.  Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. , 1993, Molecular pharmacology.

[34]  F. Monsma,et al.  Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.

[35]  D. Sibley,et al.  Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry , 1995, Neuroscience.

[36]  G. W. Price,et al.  Pharmacological profile of SB-357134: A potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist , 2002, Pharmacology Biochemistry and Behavior.

[37]  M. Pangalos,et al.  The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models , 2000, Journal of Neuroscience Methods.

[38]  Roland L. Dunbrack.  Rotamer libraries in the 21st century. , 2002, Current opinion in structural biology.